A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
NCT ID: NCT04854668
Last Updated: 2023-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
748 participants
INTERVENTIONAL
2020-07-30
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anlotinib + CapeOx
Anlotinib combined with CapeOx(Oxaliplatin+Capecitabine) were used for 4-8 cycles, each cycle is 3 weeks. After 8 cycles, the regimen is changed to Anlotinib combined with Capecitabine.
Anlotinib hydrochloride capsule
Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
Oxaliplatin
Oxaliplatin 130mg/m2, intravenous drip, on Day 1；
Capecitabine
Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
Bevacizumab + CapeOx
Bevacizumab combined with CapeOx(Oxaliplatin+Capecitabine) were used for 4-8 cycles, each cycle is 3 weeks. After 8 cycles, the regimen is changed to Bevacizumab combined with Capecitabine.
Bevacizumab
Bevacizumab 7.5mg/kg, intravenous drip, on Day 1
Oxaliplatin
Oxaliplatin 130mg/m2, intravenous drip, on Day 1；
Capecitabine
Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anlotinib hydrochloride capsule
Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
Bevacizumab
Bevacizumab 7.5mg/kg, intravenous drip, on Day 1
Oxaliplatin
Oxaliplatin 130mg/m2, intravenous drip, on Day 1；
Capecitabine
Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
3\. Histologically or cytologically confirmed unresectable metastatic colorectal cancer.
4\. Has RAS/BRAF wild-type. 5. Has at least one measurable lesion. 6. Adequate organ function. 7.Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ; No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization.
Exclusion Criteria
1. Previous or co-existing malignancies within 3 years except for cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors；
2. Has many factors that affect the oral administration of drugs；
3. Has Gastrointestinal bleeding or perforation within 4 weeks before the first dose；
4. Has active inflammatory bowel disease within 4 weeks before the first dose；
5. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage；
6. Patients whose adverse events (except hair loss) caused by previous treatment did not recover to ≤CTCAE 1 degree；
7. Has received major surgical procedure、biopsy or obvious traumatic injury within 28 days before the first dose；
8. Imaging (CT or MRI) shows that tumor invades large blood vessels or the boundary of blood vessels is unclear；
9. Has any bleeding event or the level of bleeding events ≥ CTCAE 3；
10. Has unhealed wounds, ulcerative or fractures；
11. Has arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism；
12. Has a history of psychotropic substance abuse and are unable to quit ；
13. Has any severe and / or uncontrolled disease； 3.Tumor related symptoms and treatment
<!-- -->
1. Has received chemotherapy, surgery, radiotherapy, and other anti-cancer therapy within 4 weeks before the first dose.
2. Has received anti-tumor Chinese patent medicine which were approved by NMPA Within 2 weeks before the first dose.
3. Previous adjuvant therapy containing anti-vascular or anti-EGFR targeted drugs.
4. Has received systematic treatment for advanced colorectal cancer.
5. Has symptomatic brain metastases or control of symptoms \< 2 month. 4.Has participated in other anticancer drug clinical trials within 4 weeks. 5.According to the judgement of the researchers, there are other factors that may lead to the termination of the study.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The People's Hospital of Chizhou
Chizhou, Anhui, China
Fujian Medical University Union Hospital
Fuzhou, Anhui, China
Anhui Provincial Hospital
Hefei, Anhui, China
Anhui Cancer Hospital
Hefei, Anhui, China
Xuancheng People's Hospital
Xuancheng, Anhui, China
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Peking University Frist Hospital
Beijing, Beijing Municipality, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Fuling Hospital Affiliated to Chongqing University
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
Gansu Provincial Hospital
Lanzhou, Gansu, China
Lanzhou University Second Hospital
Lanzhou, Gansu, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
The First Affiliated Hospital Of Guangzhou Medical University
Guangzhou, Guangdong, China
Qingyuan People's Hospital
Qingyuan, Guangdong, China
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China
Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China
Liuzhou Workers' Hospital
Liuzhou, Guangxi, China
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China
The First Hospital of Qinhuangdao
Qinhuangdao, Hebei, China
Tangshan People's Hospital
Tangshan, Hebei, China
The First Affiliated Hospital of Hebei North University
Zhangjiakou, Hebei, China
Harbin Medical University Affiliated Cancer Hospital
Harbin, Heilongjiang, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Huaihe Hospital of Henan University
Kaifeng, Henan, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Nanyang Second General Hospital
Nanyang, Henan, China
Xinyang Central Hospital
Xinyang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of ZhengZhou University
Zhengzhou, Henan, China
Tongji Hospital Affiliated to Tongji Medical College Hust
Wuhan, Hubei, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Xiangyang Central Hospital
Xiangyang, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Affiliated Hospital of Chifeng University
Chifeng, Inner Mongolia, China
Chifeng Municipal hospital
Chifeng, Inner Mongolia, China
The First Peoples Hospital of Changzhou
Changzhou, Jiangsu, China
Jiangsu Cancer hospital
Nanjing, Jiangsu, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
Nanjing First Hospital
Nanjing, Jiangsu, China
Nanjing Hospital of C.M.
Nanjing, Jiangsu, China
Jiangsu Province People's Hospital
Nanjing, Jiangsu, China
Jiangsu Taizhou People's Hospital
Taizhou, Jiangsu, China
Taizhou Second People's Hospital
Taizhou, Jiangsu, China
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
Subei People's Hospital of Jiangsu Province
Yangzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
JiangXi PingXiang People's Hospital
Pingxiang, Jiangxi, China
Jilin Province FAW General Hospital
Changchun, Jilin, China
Jilin Cancer Hospital
Changchun, Jilin, China
Meihekou Central Hospital
Meihekou, Jilin, China
Yanbian University Hospital
Yanji, Jilin, China
The First Affiliatde Hospital of DaLin Medical University
Dalian, Liaoning, China
The First Affiliated Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China
Genertec Liaoyou Gem Flower Hospital
Panjin, Liaoning, China
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Inner Mongolia Autonomous Region Cancer Hospital
Hohhot, Neimenggu, China
Qinghai University Affiliated Hospital
Xining, Qinghai, China
3201 Hospital
Hanzhong, Shaanxi, China
Hanzhong Central Hospital
Hanzhong, Shaanxi, China
Xi'an International Medical Center Hospital
Xi'an, Shaanxi, China
Shaanxi Provincial People's Hospital
Xi'an, Shaanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
The Second Affiliated Hospital of PLA Air Force Military Medical University
Xi'an, Shaanxi, China
Shandong Cancer Hospital Affiliated to Shandong Univercity
Jinan, Shandong, China
Affiliated Hospital of Jining Medical University
Jining, Shandong, China
Liaocheng People's Hospital
Liaocheng, Shandong, China
Weifang Hospital of Traditional Chinese Medicine
Weifang, Shandong, China
Yantai Yuhuangding Hospital
Yantai, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Longhua Hospital Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, China
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Changzhi People's Hospital
Changzhi, Shanxi, China
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Peking University BinHai Hospital
Tianjin, Tianjin Municipality, China
The First People's Hospital of Kashgar
Kashgar, Xinjiang, China
Affiliated Tumor Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Yunnan Cancer Hospital
Kunming, Yunnan, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Huzhou Cancer Hospital
Huzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
He J, Liu Y, Liu C, Hu H, Sun L, Xu D, Li J, Wang J, Chen X, Lin R, Jiang Y, Zhang Y, Zhang W, Cheng Y, Wu X, Fang M, Li E, Xu Y, Chen Y, Li J, Cui Y, Pan Z, Zhang S, Yuan Y, Ding K. A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231152350. doi: 10.1177/15330338231152350.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALTN-Ⅲ-02
Identifier Type: -
Identifier Source: org_study_id